Christopher E. Dahle

Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization

George J. Weiner, Hsin-Ming Liu, James E. Wooldridge et al. · Proceedings of the National Academy of Sciences · 1997 · 522 citations

Life Sciences, Immunology, Oncology +17

A Polymorphism in the Complement Component<i>C1qA</i>Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma

Emilian Racila, Brian K. Link, Wen‐Kai Weng et al. · Clinical Cancer Research · 2008 · 153 citations · Full text

Life Sciences, Hematology, Immunology +15

Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor

Hsin-Ming Liu, Sally E. Newbrough, Sudershan K. Bhatia et al. · Blood · 1998 · 123 citations

Life Sciences, Immunology, Molecular Biology +14

Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism

Suresh Veeramani, Siao‐Yi Wang, Christopher E. Dahle et al. · Blood · 2011 · 121 citations · Full text

Life Sciences, Hematology, Immunology +16

CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.

Heidi H. van Ojik, Lisette Bevaart, Christopher E. Dahle et al. · PubMed · 2003 · 93 citations

Life Sciences, Immunology, Oncology +15